Secure a strategic foothold in Scotland’s world-leading "Biotech Gold Coast." This boutique Clinical Research Organisation (CRO) generates a steady £191k turnover by providing mission-critical operational support to life science firms. With a lean structure and an adjusted EBITDA of £79k, it is the perfect entry-level "Service Asset" for 2026 investors looking to capitalize on the UK’s post-Brexit R&D surge.